by uimmodulon_admin | 21st November 2019 | archive
Positive results from phase 1 follow up study supports current phase 2 clinical trial of IMM-101 in combination with checkpoint inhibitor therapy Immodulon, the immuno-oncology company, today announces that long-term survival data from its phase 1 study in 18 patients...
by Sandi Greenwood | 24th October 2019 | archive
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer | British Journal of Cancer (nature.com) Dalgleish, A., Stebbing, J., Adamson, D. et al. Randomised, open-label, phase II study of gemcitabine with and...
by uimmodulon_admin | 13th September 2019 | archive
Phase 1/2 study to investigate safety and efficacy of IMM-101 in locally advanced pancreatic cancer Uxbridge, UK, 13 September 2019 – Immodulon, the immuno-oncology company, today announces that the Department of Surgery at the Erasmus Medical Center in Rotterdam is...
by uimmodulon_admin | 8th August 2019 | archive
Professor Abila brings extensive experience in clinical drug development. Immodulon, the immuno-oncology company, announces the appointment of Professor Bams Abila, MD, PhD, FFPM, as Chief Medical Officer (CMO) of the Company with immediate effect. Professor Abila has...
by uimmodulon_admin | 25th July 2019 | archive
Biomarker Research for IMM-101 Utilizing the Biodesix Diagnostic Cortex™ Platform BOULDER, Colo. and UXBRIDGE, UK, July 25, 2019 – Biodesix Inc. and Immodulon Therapeutics Limited, the immune-oncology company, today announced that they have entered into a...
by uimmodulon_admin | 27th June 2019 | archive
Amsterdam, The Netherlands and Uxbridge, UK, 27 June, 2019 – myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and Immodulon, an immuno-oncology company, today announced a collaboration...
by uimmodulon_admin | 21st June 2019 | archive
Immodulon, the immuno-oncology company, today announces the appointment of Dr Michael Bowles, as Medical Director, with immediate effect. Dr Ruslan Croitoru has chosen to step down as Chief Medical Officer to pursue other interests. A search for a new CMO is underway....
by uimmodulon_admin | 23rd May 2019 | archive
Dr Kleen brings extensive experience in immunology and immune monitoring to help further advance the company’s lead, novel immuno-oncology product, IMM-101 Uxbridge, UK, 23 May 2019 – Immodulon, the immuno-oncology company, today announces the appointment of Thomas O....
by uimmodulon_admin | 9th November 2018 | archive
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer | British Journal of Cancer (nature.com) Dalgleish, A., Stebbing, J., Adamson, D. et al. Randomised, open-label, phase II study of gemcitabine with and...
by uimmodulon_admin | 17th October 2018 | archive
Immodulon, the immuno-oncology company, is pleased to announce that Ruslan Croitoru (MD MSc (Oxon) MFPM) will be joining the Immodulon Core Management Team as the Chief Medical Officer. Ruslan is a cardiologist. He gained his medical degree in Moldova, where he...